

Lucia Del Vecchio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9221625/publications.pdf>

Version: 2024-02-01

14
papers

1,020
citations

1162367

8
h-index

1125271

13
g-index

14
all docs

14
docs citations

14
times ranked

1324
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1346-1359. | 0.4 | 628 |
| 2 | Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. <i>Lancet, The</i> , 2017, 389, 2117-2127. | 6.3 | 278 |
| 3 | Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 10-25. | 0.4 | 30 |
| 4 | A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease. <i>Drugs</i> , 2021, 81, 1491-1511. | 4.9 | 18 |
| 5 | Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 267-274. | 0.4 | 13 |
| 6 | Intravenous iron therapy and the cardiovascular system: risks and benefits. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1067-1076. | 1.4 | 12 |
| 7 | Rituximab Therapy for Adults with Nephrotic Syndromes: Standard Schedules or B Cell-Targeted Therapy?. <i>Journal of Clinical Medicine</i> , 2021, 10, 5847. | 1.0 | 11 |
| 8 | Impact of European medicines agency recommendations for hypersensitivity reactions on intravenous iron prescription in haemodialysis centres of the Lombardy region. <i>Journal of Nephrology</i> , 2016, 29, 673-681. | 0.9 | 8 |
| 9 | Safety and Efficacy of Eculizumab Therapy in Multiple Sclerosis: A Case Series. <i>Brain Sciences</i> , 2021, 11, 1341. | 1.1 | 7 |
| 10 | Is it the agent or the blood pressure level that matters for renal and vascular protection in chronic nephropathies?. <i>Kidney International</i> , 2005, 67, S15-S19. | 2.6 | 6 |
| 11 | The evolution of the therapeutic approach to membranous nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 768-773. | 0.4 | 5 |
| 12 | Ferric Carboxymatose in Non-Hemodialysis CKD Patients: A Longitudinal Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1322. | 1.0 | 2 |
| 13 | Nefecon (targeted-release formulation-budesonide) for the treatment of IgA nephropathy. <i>Future Rare Diseases</i> , 2021, 1, . | 0.1 | 2 |
| 14 | The treatment of membranous nephropathy: a journey in the search for evidence. <i>Journal of Nephrology</i> , 2022, , 1. | 0.9 | 0 |